Roche breast cancer drug gets FDA approval
Maryland, October 1, 2013
US health regulators expanded the approval of Roche Holding's breast cancer drug Perjeta and will now allow its use to help shrink tumors prior to surgery, the Food and Drug Administration said on Monday.
The decision followed a 13-0 vote by an FDA advisory panel earlier this month in favour of the expanded approval.
Perjeta was originally approved in 2012 to treat patients with advanced or late-stage HER2-positive breast cancer. It can now be used prior to surgery in patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at high risk of having their cancer return or spread, the agency said.
"By making effective therapies available to high-risk patients in the earliest disease setting, we may delay or prevent cancer recurrences," Dr Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA Center for Drug Evaluation and Research, said in a statement.
Under the expanded approval, Perjeta, known chemically as pertuzumab, would be used in combination with Roche's older breast cancer drug Herceptin and chemotherapy prior to surgery.
Herceptin has long been used to treat HER2-positive breast cancer to reduce the risk of disease recurrence. About 20 per cent of breast cancers have an abundance of the HER2 protein and tend to be aggressive, faster growing cancers.
Following surgery, patients who had been treated with Perjeta should continue to take Herceptin for a year, the FDA said. - Reuters
More Health & Environment Stories
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted
- UAE-France discuss healthcare collaboration
- Seha focus on patient centred services